Briefs: Ami Organics and Panacea Biotec
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Receives registration of Valganciclovir powder for oral solution in Germany
Panacea Biotec has reported total income of Rs. 135.27 crores during the period ended June 30, 2023
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Subscribe To Our Newsletter & Stay Updated